Asthma Treatment Market

Asthma Treatment Market (Treatment Type: Long-term Asthma Control Medications and Quick-relief Medications; and Route of Administration: Inhaled, Oral, Intravenous, and Subcutaneous) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Asthma Treatment Market Outlook 2031

  • The global industry was valued at US$ 24.0 Bn in 2021
  • It is projected to grow at a CAGR of 3.7% from 2022 to 2031 and reach more than US$ 34.5 Bn by the end of 2031

Analysts’ Viewpoint

Increase in awareness about asthma treatment is expected to drive the global asthma treatment market size during the forecast period. Participation of several organizations such as the Centers for Disease Control and Prevention’s National Asthma Control Program to increase awareness about asthma and its treatment is estimated to boost market development. Furthermore, asthma camps conducted by the Asthma Society of India are anticipated to augment the industry during the forecast period.

Rise in prevalence of asthma, increase in adoption of combination therapy, and surge in focus on development of smart/digital inhalers are propelling the demand for asthma treatment. Furthermore, several companies are engaging in collaborations and focusing on product innovation, which is likely to increase the demand for asthma medications. For instance, AstraZeneca partnered with the Avillion Company to develop ‘PT027,’ an asthma rescue inhaler.

Asthma Treatment Market

Asthma Treatment Market Introduction

Asthma is a condition, in which the airways narrow and swell, resulting in extra mucus formation. This can make breathing difficult and cause coughing, a whistling sound, and shortness of breath. Asthma is a minor annoyance for some people. For some, it can be a major issue that disrupts daily activities and could result in a life-threatening asthma attack, which is also called asthma exacerbation.

Symptoms in some people worsen in situations such as exercise-induced asthma, which could be exacerbated by cold and dry air. Irritants in the workplace such as chemical fumes, gases, or dust cause occupational asthma. Airborne allergens such as pollen, mold spores, cockroach waste, or skin and dried saliva shed by pets cause allergy-induced asthma.

Asthma medications include nebulizers and spacers. Nebulizer is preferred for asthma patients. It is a device that can deliver doses of medicines quickly and easily to asthma patients.

Increase in Disease Burden in Adults and Children Driving Market Progress

Asthma is a major public health issue that affects millions of people across the globe. Genetics or environmental factors, such as microbial exposure, passive smoking, and air pollution, are increasing the disease burden in both adults and children, thereby driving the need for asthma medications.

According to the WHO, asthma affected about 262 million people and 455,000 people succumbed to the disease in 2019. Majority of asthma-related deaths occur in low- and lower-middle-income countries, where underdiagnosis and undertreatment are common.

According to CDC, asthma affects nearly 26 million people in the U.S. The disease is estimated to cost more than US$ 56 Bn annually to the society. Thus, increase in number of asthma patients is projected to drive the demand for treatments for asthma during the forecast period.

Rise in Awareness about Asthma Attack Treatment to Boost Market Statistics

Asthma is one of the common lifelong chronic diseases. People are increasingly becoming aware about asthma and its treatment. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) to improve awareness about asthma attack treatment across the world. The entire month of May is designated as National Asthma and Allergy Awareness Month to help manage asthma and educate people to raise awareness and improve lives for all. People are aware of common treatment options for asthma such as pressurized metered dose inhalers and dry powder inhalers.

CDC’s National Asthma Control Program aims to support the people in the U.S. in treating asthma in order to achieve better health and improve the quality of life. The program funds states, school programs, and non-government organizations to help them improve their surveillance of asthma, train healthcare professionals, educate individuals and their families about asthma, and explain asthma to the public.

Effective Treatment Augmenting Long-term Asthma Control Medications Segment

In terms of treatment, the global asthma treatment market has been bifurcated into long-term asthma control medications and quick-relief (rescue) medications. The long-term asthma control medications segment dominated the industry in 2021. It is the most effective treatment choice for asthma. Inhaled corticosteroids (ICS) are the most potent and effective long-term asthma medications. GlaxoSmithKline plc's ADVAIR DISKUS and AstraZeneca's Symbicort are vital long-term asthma medications that hold major share in the business.

High Preference for Inhaled Drugs

Based on route of administration, the global market has been classified into inhaled, oral, intravenous, and subcutaneous. The inhaled segment held major share in 2021. Inhaled drug therapy is the most preferred asthma attack treatment, as the drug is directly absorbed into the epithelium of the lung.

Increase in Number of Asthma Therapeutics Dispensed Fueling Retail Pharmacies Segment

In terms of distribution channel, the global asthma treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for the largest share in 2021. This can be ascribed to the increase in number of asthma therapeutics being dispensed through retail pharmacies and rise in the number of retail pharmacies in developing countries.

Regional Analysis of Asthma Treatment Industry

North America accounted for major market share in 2021. This can be ascribed to recent FDA approvals, large number of drugs in pipeline, rise in focus on reducing the number of undiagnosed asthma cases, and availability of early treatment in the region. According to the CDC, in 2017, asthma caused an estimated 1.6 million emergency department (ED) visits and 183,000 hospitalizations in the U.S.

The market in Asia Pacific is expected to expand at a higher CAGR during the forecast period. This can be ascribed to high prevalence of asthma, increase in smoking, and rise in environmental pollution in China and India. According to a study published in the Lung India journal, with an estimated 1.5 crore to 2 crore asthma patients, at least one in every 10 asthma patients globally is from India. Increase in focus on respiratory disease management and rise in awareness about managing asthma are fueling market expansion in the region.

Analysis of Key Players

The global asthma treatment market is consolidated, with the presence of a small number of large companies. Expansion of product portfolio and mergers & acquisitions are the major strategies adopted by the key players. Leading players in the business are Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries.

Key Developments

  • In June 2022, Glenmark Pharmaceuticals launched its first fixed-dose combination FDC drug, Indamet, for asthma patients
  • In August 2021, Lupin Pharmaceuticals, one of the renowned pharmaceutical companies, launched its generic drug for asthma in the U.S.
  • In June 2021, Lupin Pharmaceuticals launched a digital asthma educator platform to guide the patients on the correct technique of using inhalers

Leading players have been profiled in the market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Asthma Treatment Market Snapshot

Attribute

Detail

Size in 2021

US$ 24.0 Bn

Forecast (Value) in 2031

More than US$ 34.5 Bn

Growth Rate

(CAGR)

3.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Treatment Type
    • Long-term Asthma Control Medications
    • Quick-relief (Rescue) Medications
  • Route of Administration
    • Inhaled
    • Oral
    • Intravenous
    • Subcutaneous
  • Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Mylan N.V.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis International AG
  • Sanofi
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global asthma treatment market in 2021?

It was valued at US$ 24.0 Bn in 2021

How big the business is expected to be in 2031?

The industry is projected to reach more than US$ 34.5 Bn by 2031.

What was the CAGR from 2017 to 2021?

The CAGR stood at 3.2% from 2017 to 2021

What is the CAGR projected to be during the forecast period?

The market is anticipated to grow at a CAGR of 3.7% from 2022 to 2031

What are the prominent trends that boost growth?

Increase in adoption of combination therapy and rise in prevalence of asthma

Which region is likely to account for major share during the forecast period?

North America is expected to account for the largest share

Who are the prominent players in the global market?

Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Asthma Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Asthma Treatment Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Bn)

    5. Key Insights

        5.1. Key Industry Events (Mergers & Acquisitions, Treatment Type Launches, Partnerships, etc.)

        5.2. Pipeline Analysis

        5.3. Regulatory Scenario by Region/Globally

        5.4. COVID-19 Pandemic Impact on the Industry

    6. Global Asthma Treatment Market Analysis and Forecast, by Treatment Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2017–2031

            6.3.1. Long-term Asthma Control Medications

            6.3.2. Quick-relief (Rescue) Medications

        6.4. Market Attractiveness Analysis, by Treatment Type

    7. Global Asthma Treatment Market Analysis and Forecast, by Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Inhaled

            7.3.2. Oral

            7.3.3. Intravenous

            7.3.4. Subcutaneous

        7.4. Market Attractiveness Analysis, by Route of Administration

    8. Global Asthma Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Retail Pharmacies

            8.3.2. Hospital Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Asthma Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Asthma Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2017–2031

            10.2.1. Long-term Asthma Control Medications

            10.2.2. Quick-relief (Rescue) Medications

        10.3. Market Value Forecast, by Route of Administration, 2017–2031

            10.3.1. Inhaled

            10.3.2. Oral

            10.3.3. Intravenous

            10.3.4. Subcutaneous

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Retail Pharmacies

            10.4.2. Hospital Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Treatment Type

            10.6.2. By Route of Administration

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Asthma Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2017–2031

            11.2.1. Long-term Asthma Control Medications

            11.2.2. Quick-relief (Rescue) Medications

        11.3. Market Value Forecast, by Route of Administration, 2017–2031

            11.3.1. Inhaled

            11.3.2. Oral

            11.3.3. Intravenous

            11.3.4. Subcutaneous

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Retail Pharmacies

            11.4.2. Hospital Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Treatment Type

            11.6.2. By Route of Administration

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Asthma Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2017–2031

            12.2.1. Long-term Asthma Control Medications

            12.2.2. Quick-relief (Rescue) Medications

        12.3. Market Value Forecast, by Route of Administration, 2017–2031

            12.3.1. Inhaled

            12.3.2. Oral

            12.3.3. Intravenous

            12.3.4. Subcutaneous

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Retail Pharmacies

            12.4.2. Hospital Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Treatment Type

            12.6.2. By Route of Administration

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Asthma Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2017–2031

            13.2.1. Long-term Asthma Control Medications

            13.2.2. Quick-relief (Rescue) Medications

        13.3. Market Value Forecast, by Route of Administration, 2017–2031

            13.3.1. Inhaled

            13.3.2. Oral

            13.3.3. Intravenous

            13.3.4. Subcutaneous

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Retail Pharmacies

            13.4.2. Hospital Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Treatment Type

            13.6.2. By Route of Administration

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Asthma Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment Type, 2017–2031

            14.2.1. Long-term Asthma Control Medications

            14.2.2. Quick-relief (Rescue) Medications

        14.3. Market Value Forecast, by Route of Administration, 2017–2031

            14.3.1. Inhaled

            14.3.2. Oral

            14.3.3. Intravenous

            14.3.4. Subcutaneous

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Retail Pharmacies

            14.4.2. Hospital Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Treatment Type

            14.6.2. By Route of Administration

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share/Ranking Analysis, by Company (2021)

        15.3. Company Profiles

            15.3.1. Mylan N.V.

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Strategic Overview

            15.3.2. AstraZeneca plc

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Strategic Overview

            15.3.3. Boehringer Ingelheim

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Strategic Overview

            15.3.4. F. Hoffmann-La Roche Ltd.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Strategic Overview

            15.3.5. GlaxoSmithKline plc.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Strategic Overview

            15.3.6. Glenmark Pharmaceuticals

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Strategic Overview

            15.3.7. Lupin Pharmaceuticals

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Strategic Overview

            15.3.8. Merck & Co. Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Strategic Overview

            15.3.9. Novartis International AG

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Strategic Overview

            15.3.10. Sanofi

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Strategic Overview

            15.3.11. Sunovion Pharmaceuticals, Inc.

                15.3.11.1. Company Overview

                15.3.11.2. Product Portfolio

                15.3.11.3. SWOT Analysis

                15.3.11.4. Strategic Overview

            15.3.12. Teva Pharmaceutical Industries

                15.3.12.1. Company Overview

                15.3.12.2. Product Portfolio

                15.3.12.3. SWOT Analysis

                15.3.12.4. Strategic Overview

    List of Tables

    Table 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 02: Global Asthma Treatment Market Value (US$ Bn) Forecast, by 2017‒2031, by Route of Administration

    Table 03: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 05: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2031

    Table 06: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 07: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

    Table 08: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 11: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

    Table 12: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 15: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

    Table 16: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 19: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

    Table 20: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

    Table 23: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

    Table 24: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 02: Global Asthma Treatment Market Value Share, by Treatment Type, 2021

    Figure 03: Global Asthma Treatment Market Value Share, by Route of Administration, 2021

    Figure 04: Global Asthma Treatment Market Value Share, by Distribution Channel, 2021

    Figure 05: Global Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 06: Global Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 07: Global Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 08: Global Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 09: Global Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 10: Global Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 11: Global Asthma Treatment Market Value Share Analysis, by Region, 2021 and 2031

    Figure 12: Global Asthma Treatment Market Attractiveness Analysis, by Region, 2022–2031

    Figure 13: North America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 14: North America Asthma Treatment Market Value Share Analysis, by Country, 2021 and 2031

    Figure 15: North America Asthma Treatment Market Attractiveness Analysis, by Country, 2022–2031

    Figure 16: North America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 17: North America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 18: North America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 19: North America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 20: North America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 21: North America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 22: Europe Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 23: Europe Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 24: Europe Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 25: Europe Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 26: Europe Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 27: Europe Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 28: Europe Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 29: Europe Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 30: Europe Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 31: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 32: Asia Pacific Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 33: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 34: Asia Pacific Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 35: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 36: Asia Pacific Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 37: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 38: Asia Pacific Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 39: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 40: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 41: Latin America Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 42: Latin America Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

    Figure 43: Latin America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 44: Latin America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 45: Latin America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 46: Latin America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 47: Latin America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 48: Latin America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 49: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

    Figure 50: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 51: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

    Figure 52: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

    Figure 53: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

    Figure 54: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 55: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 56: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 57: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 58: Company Share Analysis, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved